Search company, investor...

CF PharmTech

cfpharmtech.com

Founded Year

2007

Stage

Series F | Alive

Total Raised

$205.94M

Last Raised

$50.94M | 3 yrs ago

About CF PharmTech

CF PharmTech specializes on pharmaceuticals that focus on the development, manufacturing, and commercialization of metered dose inhaler, inhalation powder, nasal spray and blow-fill-seal products for the global market.

Headquarters Location

No. 16 Hucun Dang Road, Suxiang Cooperative Development Zone

Suzhou, Jiangsu,

China

0512-86867555

Missing: CF PharmTech's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: CF PharmTech's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing CF PharmTech

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CF PharmTech is included in 2 Expert Collections, including Medical Devices.

M

Medical Devices

8,633 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health IT

7,901 items

CF PharmTech Patents

CF PharmTech has filed 1 patent.

The 3 most popular patent topics include:

  • Beta blockers
  • Dosage forms
  • Drug delivery devices
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/4/2020

Muscarinic antagonists, Quaternary ammonium compounds, Dosage forms, Drug delivery devices, Beta blockers

Application

Application Date

6/4/2020

Grant Date

Title

Related Topics

Muscarinic antagonists, Quaternary ammonium compounds, Dosage forms, Drug delivery devices, Beta blockers

Status

Application

Latest CF PharmTech News

CF PharmTech and Chengdu Shangyi Launch the "Home-Based Recovery Program for Discharged Covid-19 Patients" and Announce Today's ...

Feb 2, 2021

News provided by Share this article SUZHOU, China, Feb. 1, 2021 /CNW/ -- CF PharmTech, Inc. is a fully integrated pharmaceutical company in China specializing in the treatment of respiratory diseases. Chengdu Shangyi Information Technology Co., Ltd is a professional IT service company in the healthcare industry in China. CF PharmTech and Chengdu Shangyi Launch the "Home-Based Recovery Program for Discharged Covid-19 Patients" and Announce Today's Global Release of the "R Plus Health" Free App In April 2020, CF PharmTech and Chengdu Shangyi launched the "Home-Based Recovery Program for Discharged Covid-19 Patients". Under the guidance of Professor Li Jian'an, a member of the American Academy of Medical Sciences and Director of the Rehabilitation Medical Center of the First Affiliated Hospital of Nanjing Medical University, they successfully conducted studies of discharged Covid-19 patients using sports rehabilitation remote monitoring by "R Plus Health" App. The clinical results exceeded everyone's expectations. Professor Li Jian'an concluded that the effect of sports rehabilitation monitoring for patients using the App was comparable to the effect from care given patients in the "Mobile Cabin Hospital" in Wuhan. The companies jointly launch the free "R Plus Health" App globally today. The App is the world's clinically proven and effective, home-based rehabilitation treatment for Covid-19 patients. It is the first "patented digital therapy" approved by the NMPA(National Medical Products Administration). The main function of the App is its remote intelligent cardiopulmonary/muscle/nutrition assessment, combining the wearable equipment with prepackaged medicinal supplements. The App will assist in improving the cardiopulmonary endurance and immunity of Covid-19 patients, susceptible populations, high-risk contacts, elderly people and children with poor immunity. Once users register, the App carries out intelligent assessments including questionnaires, and cardiopulmonary endurance and body function tests. After an evaluation, users can access a personalized exercise program including sports type, intensity, length of time and frequency. Users simply need to follow the sports training videos and do the exercises. The effect will be enhanced if the App is connected to intelligent equipment. Since the outbreak of Covid-19, more than 100 million people have been diagnosed worldwide, and the number of infected individuals is increasing rapidly. It has become a global pandemic. Join the "R Plus Health" App to enhance physical fitness, improve immunity and fight against the coronavirus. How to download: 2. Click the link: https://download.rplushealth.cn/app/patient SOURCE CF PharmTech, Inc.

CF PharmTech Frequently Asked Questions (FAQ)

  • When was CF PharmTech founded?

    CF PharmTech was founded in 2007.

  • Where is CF PharmTech's headquarters?

    CF PharmTech's headquarters is located at No. 16 Hucun Dang Road, Suxiang Cooperative Development Zone, Suzhou.

  • What is CF PharmTech's latest funding round?

    CF PharmTech's latest funding round is Series F.

  • How much did CF PharmTech raise?

    CF PharmTech raised a total of $205.94M.

  • Who are the investors of CF PharmTech?

    Investors of CF PharmTech include Hengxu Capital, BioTrack Capital, China Capital Investment Group, GP Capital, YuanMing Capital and 17 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.